19-Dec-2025
No headlines found.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 9-Dec 5:30 PM ET)
Gossamer Bio to Participate in Upcoming Investor Conferences
Business Wire (Mon, 24-Nov 4:01 PM ET)
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Business Wire (Wed, 5-Nov 4:01 PM ET)
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Globe Newswire (Wed, 22-Oct 7:00 AM ET)
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
Globe Newswire (Tue, 21-Oct 7:00 AM ET)
PRNewswire (Thu, 25-Sep 7:41 AM ET)
Business Wire (Thu, 25-Sep 7:31 AM ET)
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
Business Wire (Mon, 22-Sep 7:31 AM ET)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio trades on the NASDAQ stock market under the symbol GOSS.
As of December 19, 2025, GOSS stock price climbed to $3.44 with 14,016,554 million shares trading.
GOSS has a beta of 1.29, meaning it tends to be more sensitive to market movements. GOSS has a correlation of 0.07 to the broad based SPY ETF.
GOSS has a market cap of $796.21 million. This is considered a Small Cap stock.
Last quarter Gossamer Bio reported $13 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.02.
In the last 3 years, GOSS traded as high as $3.87 and as low as $.45.
The top ETF exchange traded funds that GOSS belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
GOSS has outperformed the market in the last year with a price return of +327.8% while the SPY ETF gained +17.3%. GOSS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.7% and +3.6%, respectively, while the SPY returned +3.3% and -0.6%, respectively.
GOSS support price is $3.26 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GOSS shares will trade within this expected range on the day.
